Brainomix, a global leader in AI-powered imaging solutions in stroke and lung fibrosis, has announced the appointment of Anna Griffin as Chief Financial Officer, filling a key leadership role within the company following its recent £14M Series C funding round.
Anna joins Brainomix from Mirada Medical, another successful Oxford-based medical imaging company, where she had worked for 15 years, progressing through a series of increasingly senior roles, including most recently as Chief Financial & Operations Officer. Anna has extensive global experience, having managed Finance and Operations in the UK, Europe and the US.
“We are delighted to have Anna on board, joining our Executive Leadership Team. Anna brings a wealth of domain expertise in medical imaging, and has demonstrated an impressive record of successfully managing operations in both the US and Europe,” said Dr Michalis Papadakis, CEO & Co-Founder of Brainomix. “As Chief Financial Officer, Anna will play an instrumental role in preparing the company for our next inflection point, as we accelerate commercial expansion in the US and advance the clinical uptake of our lung fibrosis technology.”
“I am very excited to be joining Brainomix at such a pivotal growth stage. I look forward to working closely with the leadership team and the Board as we continue our mission of delivering clinically impactful AI solutions that are transforming treatment in stroke and lung fibrosis,” said Anna Griffin.
To learn more about Anna and the rest of Brainomix's Leadership Team, click here.
